Allo-SCT followed by DLIs can establish long-term remissions in multiple myeloma (MM) patients. In many patients, however, the immunotherapeutic graft-versus-tumor (GVT) effect is moderate and not sustained, implying that immune suppression is mediated, among other factors, by regulatory T cells (Tregs) or myeloid-derived suppressor cells (MDSCs). Towards a better understanding and, eventually, manipulation of the immune-regulatory mechanisms in transplanted MM patients, we retrospectively sought a correlation between DLI outcome and circulating CD14 + MDSCs, CD14 − MDSCs and Tregs in 53 MM patients before their first DLI. We found significantly elevated frequencies of highly suppressive CD14 + MDSCs, CD14 − MDSCs and Tregs in pre-DLI samples from patients. Higher frequencies of Tregs, but not of MDSCs, were significantly associated with non-responsiveness to DLI. Furthermore, a lower frequency of Tregs predicted the development of chronic GVHD, which, in turn, displayed a high association with GVT. Elevated Treg frequencies before DLI were also associated with significantly shorter PFS and OS. Hence, our data reinforce the idea of active suppression of antitumor responses by Tregs in MM patients and therefore suggest that targeting patient Tregs before DLI may improve outcome of DLI.
INTRODUCTION
Multiple myeloma (MM) is characterized by malignant proliferation of clonal plasma cells in the BM. Although the disease is still incurable, allo-SCT followed by DLIs can induce durable responses by virtue of the graft-versus-tumor (GVT) effect in 30-50% of the patients. It is currently unknown why only a fraction of patients benefits from DLI. Furthermore, the success of the therapy is also hampered by the occurrence of GVHD. [1] [2] [3] [4] [5] This underscores the notion that the improvement of this potentially curative immunotherapy for MM will be critically dependent on the identification and proper modulation of mechanisms that control GVT and GVHD.
Research over the past decades identified several immune cells that may regulate both GVT and GVHD. Among these are the extensively studied CD4 + HLA-DR − /low myeloid cells, with variable expression of CD14, CD15 and other markers. 6 To date, numerous studies have demonstrated the protective role of Tregs on GVHD. [7] [8] [9] [10] [11] [12] However, there is no clear consensus yet on their impact on GVT. In some murine models, coinfusion of Tregs with BMT does not impair GVT, 7 ,13 a poorly understood phenomenon, which was partly confirmed for human Tregs in a xenograft model. 13 However, in other murine models, Tregs regulate not only GVHD but also GVT after DLI.
14 These latter observations gained support from clinical studies, which showed increased Treg frequencies in CML patients with relapse after allo-SCT 15 and an inverse correlation of Treg frequencies in DLI products with GVT. 16 Finally, the depletion of Tregs resulted in an improved GVT effect, strongly associated with the occurrence of GVHD, 17 suggesting, despite the initial thoughts, a detrimental role of Tregs on GVT in the clinical setting.
Like Tregs, murine MDSCs were reported to expand after allo-SCT 18 and their coinfusion or removal from the graft was associated with alleviation or aggravation of GVHD, respectively. 19, 20 A recent clinical study described an accumulation of CD14 + MDSCs after allo-SCT, especially during acute GVHD of higher grade. 21 Although MDSCs are present in increased frequencies in MM patients, inhibit T-cell proliferation and promote MM cell growth in vitro, [22] [23] [24] it is not yet known whether they can influence the outcome of cellular immunotherapy such as DLI.
To gain more insight into the impact of both 7 (n = 28) or 1 × 10 8 T cells per kg (n = 3). Therefore, the analyses were performed by categorizing the patients into two groups using the dose of 1 × 10 7 T cells per kg as a cut off value. Response to therapy and progression were assessed according to the uniform criteria of the International Myeloma Working Group. 27, 28 Response to DLI was defined as at least PR. Immunosuppressive drugs were stopped at least 1 month before DLI. Five patients received immunomodulatory drugs (lenalidomide 4, bortezomib 1) shortly before or after DLI. All analyses were performed with or without exclusion of these five patients with no significant variation in the results. Therefore, throughout the manuscript only the results of the whole cohort are presented.
OS was measured in months and defined from the date of DLI to the date of death or last follow-up. PFS was defined as the time from DLI to date of progression or death from any cause or last follow-up. Acute and chronic GVHD were defined according to the Seattle criteria and according to Shulman et al., 29 respectively, calculated from the time of DLI. 
In vitro suppression assay
To determine the suppressive capacity of MDSCs and Tregs, we performed in vitro suppression assays for three patients and four healthy controls. (Figures 1a and c) . Tregs and MDSCs were isolated from pre-DLI samples of MM patients using FACS and cocultured with autologous PBMCs for 4 days in anti-CD3-coated wells at different effector:target ratios. All sorted cell types suppressed the T-cell proliferation induced by CD3 triggering (Figure 1d ). These results confirmed that CD14 + MDSCs and CD14 − MDSCs, as well as Tregs, as defined by their surface markers in our study, represented functionally intact suppressor cell populations in the pre-DLI PBMC samples of MM patients.
Increased frequency of Tregs and MDSCs in MM patients pre-DLI After confirming the immune suppressor capacity of the Tregs and MDSC subsets, we determined the frequencies of these cell subsets in pre-DLI samples of the whole cohort of 53 MM patients (blood withdrawal: mean 9.9 days before DLI, range 0-150 days) and compared this with healthy donors (n = 13 and 16 for Tregs and MDSCs, respectively). No patients used immunosuppressants at the time of sampling and all patients were fully reconstituted. For detailed clinical characteristics of the patients see Table 1 . We observed a significantly higher frequency of CD14 + MDSCs (mean 4.45% vs 0.73%, P o 0.001), CD14
− MDSCs (mean 1.10% vs 0.61%, Po 0.01) and Tregs (mean 11.82% vs 5.59%, P o0.01) in PB of MM patients compared with healthy donors (Figure 2 ). For 16 patients, Abbreviations: ATG = anti-thymocyte globulin; MUD = matched unrelated donor; NMA = non-myeloablative; Sib = sibling donor; Tx = transplantation. + cells of MM patients after allo-SCT, pre-DLI compared with healthy donors. *P o0.05, **Po 0.01 and ***P o0.001.
we could also measure the frequencies of these subsets 1-2 months after DLI. We found no significant difference in frequencies before and after DLI (not shown). Remarkably, not all patients showed elevated levels of these suppressor cells. This suggested that, whatever the reason, the increase in Tregs and MDSCs in the PB of these extensively pretreated MM patients, months after allo-SCT, could affect DLI outcome.
High frequency of Tregs is associated with a low response to DLI To assess the possible impact of these circulating MDSCs and Tregs on DLI outcome, we first correlated their frequencies with response to DLI. We found a significantly higher level of Tregs (mean 13.73% vs 8.67%, P = 0.03; Table 2 ) in patients who did not respond to DLI, compared with responding patients. Levels of CD14 − and CD14 + MDSCs were not different between DLI responders and non-responders ( Figure 3 and Table 2 ). This indicated that high levels of Tregs, but not MDSCs, were significantly associated with non-response to DLI.
Low Treg levels pre-DLI are associated with the occurrence of chronic GVHD Among several other possible predictive factors analyzed for response to DLI, only acute and chronic GVHD showed a significant association with response ( Table 2 ). Response to DLI was 78% in patients with aGVHD and 83% in patients with cGVHD, compared with only 30% of patients without aGVHD and 24% of patients without cGVHD (P o 0.01). As suppressor cells may also influence GVHD, we also analyzed the correlation between the frequencies of Tregs, MDSCs and GVHD occurrence. Treg levels pre-DLI were significantly higher in patients without cGVHD after DLI (mean 13.08% vs 7.52%, P = 0.03; Figure 4 ). MDSCs did not show an association with cGVHD. Levels of suppressor cells before DLI showed no association with aGVHD. Other possible predictive factors for GVHD in this cohort were also tested (Supplementary Table 1) , and among these, only a higher dose of CD3 + cells was associated with increased chronic GVHD.
The frequency of Tregs pre-DLI is related to the OS and PFS in MM patients Finally, we assessed whether the levels of MDSC subsets and Tregs before DLI could predict PFS and OS. In univariate Cox analysis, higher frequencies of Tregs, but not of MDSCs, before DLI were significantly associated with a reduced PFS (P = 0.01) and OS (P = 0.001) (Supplementary Table 2 ). In a Kaplan-Meier analysis, patients with Treg levels in the highest quartile (414.6% Tregs in CD4 + T cells) had a significantly decreased PFS (P o 0.001; Figure 5a ) and OS (P o0.01; Figure 5b ) as compared with patients with lower levels. Median PFS was 4.2 months and the median OS was 25.5 months in the highest quartile vs a median PFS of 12.4 months and OS of 67 months in patients with lower levels of Tregs. After including other predictive factors for PFS and OS (see Supplementary Table 1) in multivariate Cox regression analysis, we found a trend for decreased PFS in patients with high numbers of Tregs. Response to DLI and the remission status before DLI (⩾ VGPR (very good partial response) vs rest) were independent factors influencing PFS (Table 3 ; P = 0.004 and P = 0.003 respectively). In the multivariate Cox regression analysis for OS, Treg levels (P = 0.02) and application of reinduction chemotherapy were independent predictors for OS (Table 3 ). In addition, for OS there was a trend towards significance for time from transplantation to DLI. These data show that in patients with persistent or progressive disease after allo-SCT, response to DLI is associated with a longer PFS. Furthermore, high Treg levels before DLI have a negative effect on OS, independent of response to DLI. Abbreviations: ATG = anti-thymocyte globulin; MUD = matched unrelated donor; NMA = non-myeloablative; Sib = sibling donor; Tx = transplantation; VGPR = very good partial response. Percentages are quantitated as the percentage of viable cells for MDSCs and of CD4 + T cells for Tregs.
DISCUSSION
In this study, we show that circulating MDSCs and Tregs are found at increased frequencies in a subset of MM patients with persistent or progressive disease, months after allo-SCT. The increased levels of Tregs, but not of MDSCs, are associated with an impaired response to DLI, a lower incidence of cGVHD, as well as a decreased PFS and OS. A major aim of this work was to gain insight into the possible modulation of therapeutic immune responses by MDSCs in MM patients. Despite being encountered at elevated levels in these patients, it is currently not well documented whether this suppressor cell subset can indeed modulate immune responses in MM. We also readdressed the impact of Tregs on the immunotherapeutic antitumor effect, as this is a frequently debated issue, with conflicting reports. We chose to address our questions in the DLI setting, because DLI is an important therapeutic modality for MM, and, as compared with the direct after allo-SCT setting, provides a better platform to evaluate the therapeutic impact of suppressor cells without being biased by GVHD prophylaxis, post-transplant homeostatic lymphocyte expansion and a post-transplant inflammatory state. Consistent with our goal, we correlated DLI outcome with the frequency of cell subsets present in patients before DLI. In this respect, our study differs from several others, which correlated the DLI/SCT outcome with suppressor cell levels present in the infused cell products. 10, 11, 16, 31, 32 Therefore, our findings point to a novel clinical strategy to improve the clinical outcome of DLI (see below).
With regard to MDSCs, we should note that because of the retrospective character of our study, we have not been able to analyze all previously described MDSC subsets. Especially the use of cryopreserved PBMCs, which are largely devoid of CD15 + cells, forced us to discriminate the CD33 + CD11b + HLA-DR − /low MDSCs only on the basis of their CD14 expression. Despite these limitations, consistent with recent reports, 22, 23 we found significantly elevated levels of CD14 + and CD14 − MDSCs also in transplanted MM patients, before DLI. We also confirmed their functional competence (suppressor capacity) in these patients before DLI (Figure 1d ). Thus, it seems conceivable that the expansion of these suppressor cells is driven by persistent MM. However, since the possible causes of their elevated levels were not a specific focus of our study, we did not further analyze this issue. Our focus was to analyze their clinical relevance. Despite earlier suggestions, however, we found no evidence for this: there was no association between MDSCs and DLI outcome. Yet, to be definitive, it is appropriate to study the impact of granulocyte-like MDSCs as well, but in a prospective study, using freshly isolated PBMCs.
Regarding Tregs, contradictory results have been reported in various settings. Although some, especially murine studies, found that Tregs do not hamper GVT responses, 7, 8, 13 others demonstrated the opposite. [14] [15] [16] [17] Some discrepancies between mouse and human studies may be related to species-specific aspects. We suspect however that the discrepancies could also be because murine models do not take into account the heterogeneity seen in the human setting. Underscoring this, we have found a considerable level of heterogeneity in the Treg levels in pre-DLI samples of MM patients. Remarkably, and confirming the results of several clinical studies, 16, 17 Treg levels in pre-DLI samples were clearly associated with DLI responsiveness, which in turn was a good predictor of PFS. Importantly, we also found that high levels of Tregs were associated with impaired OS. It has previously been shown that Tregs modulate OS in newly diagnosed MM patients. 33 In that report, higher percentages of Tregs were also encountered in patients who died of infectious complications, suggesting that the modulation of OS by Tregs can be multifactorial. Also in our study, possible tumor growth-promoting properties together with increased incidence of infectious complications could have been contributing to the decreased OS in patients who displayed higher levels of Tregs in the circulation, already before DLI.
Taken together, our findings showing that high pre-DLI levels of Tregs are associated with DLI non-response and decreased OS may have important clinical implications. First of all, our results suggest that GVHD prevention by Treg coinfusions in the DLI setting is not a favorable idea, because of the potential impairment of the GVT effect. Most importantly, our results suggest a careful monitoring of Treg levels before DLI, with the intention to apply a pre-DLI Treg depletion strategy. As the levels of Tregs in some patients are much higher than in healthy donors, we think that this could be a more effective strategy to improve DLI responses compared with Treg depletion from the DLI products. For example, the administration of a continuous, low dose of cyclophosphamide has been shown to selectively deplete Tregs and has also been combined with cellular immunotherapy. [34] [35] [36] [37] Administration of continuous, low-dose cyclophosphamide in those patients with elevated Treg levels compared with normal individuals before DLI could improve its antitumor effect. Furthermore, as low pre-DLI levels of Tregs do not seem to increase aGVHD incidence in our cohort, it may be possible that this in vivo Treg depletion strategy may not induce the early morbidity and mortality associated with aGVHD.
In conclusion, our analyses point to, and warrant, the clinical testing of a novel pre-DLI Treg depletion strategy towards improvement of the DLI outcome. 
